To these problems, a new EGFR-targeted ADC was synthesized, which is expected to become an effective, selective and safe therapeutic agent for EGFR-positive pancreatic cancer (Z. Li et al., 2019). This evidence concerns the gene EGFR and pancreatic neoplasm.